Before a clinical trial involving human participants can begin, a drug candidate has already gone through years of laboratory work. Scientists start by identifying a disease or condition they want to address, then they screen thousands of chemical compounds or biological molecules to find ones that might work. This stage, called drug discovery, happens entirely in test tubes and computer models. Researchers look for compounds that show promise against the target disease without causing obvious harm to cells.
Learn About Paying Your FGUA Bill Online →
Once a promising compound is identified, it moves into preclinical testing. This phase involves extensive work in laboratories using cell cultures and animal models—typically mice, rats, or sometimes dogs and primates. Preclinical testing answers crucial questions: Does the compound actually affect the disease? What happens to it inside a living body? How does it get processed and eliminated? At what dose does it start causing harm? These experiments can take 3 to 6 years and cost millions of dollars. Many compounds fail at this stage and never move forward.
The transition from preclinical to clinical work is significant. Clinical trials involve real people, which means the stakes are higher and regulations become much stricter. Before any human can receive an experimental drug, the company or research institution must compile all their laboratory and animal data and submit it for review. They must demonstrate that the potential benefits of testing in humans outweigh the known risks based on what they've learned so far.
This is where the Investigational New Drug (IND) application comes in. The IND is not a permission to treat patients—it's permission to begin testing in people. The FDA reviews the IND application to determine whether the proposed trial is scientifically sound and whether human participants can be reasonably protected from harm based on what's known so far.
Key takeaway: Years of bench research and animal testing precede any human trial. Understanding this timeline helps explain why new medications take so long to reach patients and why the approval process is structured the way it is.
An Investigational New Drug application is a detailed document package submitted to the FDA that asks for permission to test a new drug in people. Think of it as a comprehensive research proposal combined with a safety dossier. The IND application includes the proposed clinical trial protocol (the detailed plan for how the study will be conducted), summaries of all prior research, pharmacology and toxicology data from animal studies, manufacturing information, and the investigator's brochure—a document that compiles everything known about the drug's effects.
Free Guide to Pay by Plate Illinois Billing →
The FDA has specific timelines for reviewing IND applications. The agency has 30 calendar days to decide whether to allow the trial to proceed, place a clinical hold (pause the trial), or request more information. This doesn't mean the FDA makes a decision in 30 days in all cases—complex applications often involve back-and-forth communication. However, the 30-day clock means the FDA cannot simply sit on an IND indefinitely without communicating with the sponsor.
When the FDA reviews an IND, they focus on several key areas. First, they assess whether the proposed trial design is scientifically sound—does the study actually test what it claims to test? Second, they examine the informed consent document that will be given to participants; this must clearly explain what is known and unknown about the drug, what procedures participants will undergo, and what risks exist. Third, they review the qualifications of the investigator (the lead researcher) and the research facilities. Fourth, they evaluate whether the proposed starting dose and study population are reasonable given the animal toxicity data.
If the FDA has concerns, they issue a clinical hold letter explaining what must be addressed before the trial can begin. Common reasons for clinical holds include unclear informed consent language, inadequate animal toxicity data, insufficient information about the drug's chemistry and manufacturing, or concerns that the starting dose is too high given the animal data. The sponsor then has the opportunity to address the FDA's concerns and resubmit.
Once the FDA allows the IND to proceed, this doesn't mean the trial automatically starts. The research site's Institutional Review Board (IRB)—an independent committee that reviews research involving human subjects—must also review and approve the protocol. Only after both the FDA and the IRB approve can enrollment begin.
Key takeaway: The IND application is where the FDA first evaluates whether testing a new drug in humans is justified by the preclinical evidence. This process typically takes weeks to months and involves multiple rounds of communication between the FDA and the drug sponsor.
Clinical trials for new drugs are organized into phases, each with different goals and different numbers of participants. Understanding these phases provides insight into how safety and effectiveness are evaluated step by step, rather than all at once.
Free Guide to Mold Removal Methods for Walls →
Phase 1 trials are the first time a drug is tested in humans. These studies involve small groups—typically 20 to 100 healthy volunteers (or sometimes patients if the drug is too toxic to give to healthy people, such as cancer drugs). Phase 1 is primarily about safety and tolerability. Researchers want to know: How is the drug absorbed, distributed, and eliminated from the body? What side effects occur? Is there a dose that seems safe? Researchers carefully increase the dose in small increments, watching for side effects, before moving to a higher dose. Phase 1 trials typically last several months to a year. These trials do not test whether the drug actually treats the disease—that's not the goal yet.
Phase 2 trials expand the participant pool to several hundred people who have the disease being targeted. Now the focus shifts: Does the drug actually work for the intended purpose? Researchers continue to monitor safety, but they now also measure whether patients improve. For example, a Phase 2 trial for a diabetes drug would measure whether participants' blood sugar levels improve. These trials are larger and more complex than Phase 1 and typically last several months to two years. Many drugs fail at Phase 2 because they don't show enough effectiveness, even if they were safe in Phase 1.
Phase 3 trials involve large populations—often 1,000 to 5,000 participants—and aim to confirm that the drug works and monitor for side effects in a diverse population. These trials often compare the new drug to existing treatments (or a placebo if no good treatment exists) to see if the new drug is better, equally effective, or perhaps has a better side effect profile. Phase 3 is where most of the regulatory decisions are made. These trials can last one to three years or longer.
Phase 4 trials occur after a drug has been approved and is on the market. These are post-marketing studies used to monitor long-term effects, compare the drug to other treatments in real-world settings, or investigate new uses for the drug. Phase 4 trials help answer questions that couldn't be studied before approval—for instance, long-term safety effects that only become apparent after many people have used the drug for years.
Key takeaway: Each trial phase answers different questions using progressively larger populations. This staged approach distributes risk: researchers don't move forward with larger groups until smaller groups have demonstrated reasonable safety and evidence of effect.
An Institutional Review Board (IRB) is an independent committee, usually located at a hospital or research institution, that reviews research studies involving human participants. The IRB is not part of the FDA—it's a separate safeguard built into the research system. Every clinical trial must have IRB approval before it starts and must continue to have IRB oversight throughout the study.
How to Delete Your Fitbit Account Guide →
IRBs typically include physicians, scientists, ethicists, and community members. Their job is to protect the rights and welfare of research participants. When reviewing a clinical trial protocol, the IRB examines the informed consent document carefully. They ask: Is the language clear to a non-scientist? Are the risks described accurately? Are participants told about alternative treatments available outside the study? Is the study design ethical? Is the researcher qualified? IRBs can approve a study, request modifications before approval, or deny approval.
Throughout a trial, IRBs continue to monitor safety. Researchers must report any serious or unexpected adverse events to both the IRB and the FDA. If a participant has a heart attack, stroke, hospitalization, or death during the trial, this must be reported. IRBs review these reports and can halt a trial if the reported events suggest the drug is too dangerous to continue testing.
The FDA also monitors ongoing safety through several mechanisms. Sponsors must submit periodic reports to the FDA with safety updates and any changes to the trial protocol. The FDA maintains
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.